FDA.reportPublic FDA data

RUXOLITINIB Pharmacologic Class Indexing

Class set ID
f8ace083-bdca-4b67-8154-6efe6c827776
Version
3
Effective date
20220322
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use JAKAFI/JAKAFI XR safely and effectively. See full prescribing information for JAKAFI/JAKAFI XR. JAKAFI ® (ruxolitinib) tablets, for oral use JAKAFI XR™ (ruxolitinib) extended-release tablets, for oral use Initial U.S. Approval: 2011Incyte Corporation2026050140
These highlights do not include all the information needed to use OPZELURA cream safely and effectively. See full prescribing information for OPZELURA cream. OPZELURA ® (ruxolitinib) cream, for topical use Initial U.S. Approval: 2011Incyte Corporation2025111113